Efficacy of rituximab versus cyclophosphamide in connective tissue disease‑related interstitial lung disease: a systematic review and meta-analysis
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-025-07533-6 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Yan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, Ganzhou, 341000, C…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Rituximab, Cyclophosphamide, Connective Tissue Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study systematically compares the efficacy and adverse events of rituximab (RTX) and cyclophosphamide (CYC) in patients with connective tissue disease-related interstitial lung disease (CTD-ILD). METHODS: The EMBASE, Cochrane, and PubMed databases were systematically searched to find all relevant studies. Quality assessment, study selection, and data extraction were independently conducted by two reviewers. The mean changes in percentage of predicted forced vital capacity (FVC%) and percentage of predicted diffusing capacity for carbon monoxide (DLco%) of the patients were selected to be primary outcome measures. RevMan 5 software was used for the pooled analysis. RESULTS: Among 1106 titles screened from multiple databases, six studies met the inclusion criteria (two randomized controlled trials and four retrospective observational studies). Patients of four studies were systemic sclerosis-related interstitial disease(SSc-ILD), one study was anti-synthetase syndrome-related interstitial lung disease (AsyS-ILD), and one study was CTD-ILD (included idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc) or mixed connective tissue disease (MCTD), rheumatoid arthritis(RA)). The summary weight mean difference of FVC% change in the RTX group compared with the CYC group was 0.86 (95% CI:-1.51,3.24; P = 0.48), and the summary weight mean difference of DLco% change in the RTX group compared with the CYC group was 6.43 (95% CI: 1.62, 11.23; P = 0.009). Our pooled analysis suggested no significant difference in FVC% improvement between RTX and CYC. RTX seems to be slightly superior to CYC in terms of DLco% improvement in our meta-analysis. However, only three out of six enrolled studies provided data on DLco% change. Therefore, the results for DLco% change should be cautiously interpreted. Studies enrolled showed that adverse events were fewer in the RTX group. RTX appears to offer a favorable balance between efficacy and safety. CONCLUSIONS: RTX demonstrated similar efficacy to CYC in improving lung function (FVC% and DLco%), with fewer adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, Ganzhou, 341000, China.
- Department of Rheumatology and Immunology, Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, Ganzhou, 341000, China. 18970101225@163.com.
Zitieren
APA
Liu, Y., Liu, Y., Xu, J., Zeng, G., Yang, Q., & Xu, S. (2025). Efficacy of rituximab versus cyclophosphamide in connective tissue disease‑related interstitial lung disease: a systematic review and meta-analysis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07533-6
Vancouver
Liu Y, Liu Y, Xu J, Zeng G, Yang Q, Xu S. Efficacy of rituximab versus cyclophosphamide in connective tissue disease‑related interstitial lung disease: a systematic review and meta-analysis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07533-6
BibTeX
@article{Liu2025,
author = {Liu, Yan and Liu, Yaoxiu and Xu, Junlai and Zeng, Guoxing and Yang, Qingyuan and Xu, Shuiming},
title = {Efficacy of rituximab versus cyclophosphamide in connective tissue disease‑related interstitial lung disease: a systematic review and meta-analysis},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-025-07533-6}
}
EUVIMED